Skip to main content

Peer Review reports

From: Clinical experience of treatment of immunocompromised individuals with persistent SARS-CoV-2 infection based on drug resistance mutations determined by genomic analysis: a descriptive study

Original Submission
26 May 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
2 Aug 2023 Reviewed Reviewer Report - Kazuhiro Itoh
12 Aug 2023 Reviewed Reviewer Report
22 Sep 2023 Author responded Author comments - Daiki Wada
Resubmission - Version 3
22 Sep 2023 Submitted Manuscript version 3
24 Sep 2023 Author responded Author comments - Daiki Wada
Resubmission - Version 4
24 Sep 2023 Submitted Manuscript version 4
25 Sep 2023 Author responded Author comments - Daiki Wada
Resubmission - Version 5
25 Sep 2023 Submitted Manuscript version 5
5 Oct 2023 Reviewed Reviewer Report - Kazuhiro Itoh
16 Oct 2023 Reviewed Reviewer Report
18 Oct 2023 Author responded Author comments - Daiki Wada
Resubmission - Version 6
18 Oct 2023 Submitted Manuscript version 6
24 Oct 2023 Reviewed Reviewer Report - Kazuhiro Itoh
30 Oct 2023 Reviewed Reviewer Report
31 Oct 2023 Author responded Author comments - Daiki Wada
Resubmission - Version 7
31 Oct 2023 Submitted Manuscript version 7
Publishing
6 Nov 2023 Editorially accepted
9 Nov 2023 Article published 10.1186/s12879-023-08797-6

You can find further information about peer review here.

Back to article page